Asia
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
Shanghai-based LianBio raised $310 million in an oversubscribed crossover financing round less than two months after the company launched.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
When Japan’s landmark regenerative medicine legislation took effect in 2014, it opened an entirely new market for biotech innovators. Athersys, a leader in regenerative medicine, seized the opportunity.
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
PRESS RELEASES